triple reuptake inhibitors (Lilly)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nametriple reuptake inhibitors (Lilly)
Drug Alias Nameserotonin, norephinephrine, dopamine combined reuptake inhibitors (Lilly)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitors
TargetsSerotonin transporterNorepinephrine transporter
Therapy Area/IndicationsDepression
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsDepression

Other Information

ATC CodeN/A
Related LinksN/A